Every material Form 8-K Ligand Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ligand reported third-quarter 2025 total revenues and other income of $115.5 million, up from $51.8 million a year earlier, and GAAP net income of $117.3 million, or $5.68 per diluted share, compared with a net loss of $7.2 million in the prior-year quarter. The quarter was helped by a $28.6 million gain on the Pelthos business sale and $24.5 million of Zelsuvmi out-license income, and the company raised its 2025 revenue and adjusted earnings per share guidance for the second time this year.
Q3 2025 total revenues and other income were $115.5 million, up 123% from $51.8 million in Q3 2024
GAAP net income was $117.3 million, or $5.68 per diluted share, versus a net loss of $7.2 million, or $0.39 per share, a year earlier
2025 total core revenue guidance raised to $225 million to $235 million from $200 million to $225 million
2025 core adjusted earnings per diluted share guidance raised to $7.40 to $7.65 from $6.70 to $7.00
Ligand Pharmaceuticals signed a Third Amendment to its credit agreement with Citibank, N.A. as administrative agent, extending the loan maturity date to September 12, 2028. The amendment also sets a minimum consolidated EBITDA covenant of $55 million for the trailing four-quarter period ending September 30, 2025 and each period after that.
Third Amendment to Credit Agreement dated September 12, 2025, with Citibank, N.A. as Administrative Agent
Maturity date extended to September 12, 2028
Minimum consolidated EBITDA covenant of $55 million for trailing four-quarter periods starting with the period ending September 30, 2025
Credit agreement originally dated October 12, 2023, previously amended July 8, 2024 and August 11, 2025
Ligand Pharmaceuticals completed a private offering of $460.0 million of 0.75% convertible senior notes due October 1, 2030, including the full exercise of a $60.0 million option, with net proceeds of approximately $445.1 million. The notes are unsecured senior obligations, so the offering adds a new debt obligation for shareholders to weigh, while the company says convertible note hedges are expected generally to reduce potential dilution from conversions.
$460.0 million aggregate principal at 0.75% interest, payable semiannually from April 1, 2026; maturity October 1, 2030
Initial conversion price of approximately $194.79 per share, a premium of approximately 32.5% to the August 11, 2025 last reported sale price
Net proceeds of approximately $445.1 million; about $45.9 million used for hedge costs and $15.0 million to repurchase 102,034 shares at $147.01 per share
Warrants have an initial strike price of $294.02 per share and could have a dilutive effect if the stock price exceeds that level; the company may not redeem the notes before October 6, 2028
Ligand Pharmaceuticals announced a proposed private placement of $400 million of convertible senior notes due 2030, with an option for initial purchasers to buy up to an additional $60.0 million. The company also amended its credit agreement with Citibank, N.A., to permit certain cash settlement payments on the notes. The offering is subject to market conditions, and the interest rate and conversion terms will be set at pricing.
Proposed $400 million aggregate principal amount of convertible senior notes maturing October 1, 2030, offered to qualified institutional buyers under Rule 144A.
Initial purchasers would have a 13-day option to buy up to an additional $60.0 million of notes.
Up to $30 million of net proceeds may be used to repurchase common stock from certain note purchasers.
Second Amendment to Credit Agreement dated August 11, 2025 permits certain cash settlement payments on the notes, subject to customary conditions.
Ligand reported second-quarter 2025 results on August 7, 2025, with total revenues and other income of $47.6 million, up 15% from $41.5 million a year earlier, and GAAP net income of $4.8 million, or $0.24 per diluted share, versus a $51.9 million loss in the same period of 2024. The company raised its full-year 2025 revenue guidance to $200 million to $225 million and its adjusted earnings per diluted share guidance to $6.70 to $7.00, which matters to shareholders because both headline measures improved and the outlook was lifted, though the six-month GAAP net loss of $37.6 million reflects a $44.3 million one-time charge.
Q2 2025 royalties were $36.4 million, up 57% from $23.2 million, mainly from Recordati's Qarziba and Travere Therapeutics' Filspari.
Q2 2025 GAAP net income was $4.8 million, or $0.24 per diluted share, compared with a GAAP net loss of $51.9 million, or $2.88 per share, in Q2 2024.
Six-month GAAP net loss was $37.6 million, or $1.95 per share, including a $44.3 million one-time charge tied to the Castle Creek Biosciences royalty financing agreement.
2025 revenue guidance rose to $200 million to $225 million from $180 million to $200 million; adjusted EPS guidance rose to $6.70 to $7.00 from $6.00 to $6.25.
Ligand reported first quarter 2025 total revenues and other income of $45.3 million, up 46% from $31.0 million a year earlier, driven by higher royalty and Captisol revenue. The company posted a GAAP net loss of $42.5 million, or $2.21 per share, compared with GAAP net income of $86.1 million, or $4.75 per diluted share, a year earlier, mainly due to a $44.3 million one-time charge tied to the Castle Creek royalty financing. Ligand reaffirmed its 2025 guidance of $180 million to $200 million in total revenue and adjusted earnings per diluted share of approximately $6.00 to $6.25.
Total revenues and other income were $45.3 million, up from $31.0 million; royalties were $27.5 million and Captisol sales were $13.5 million
GAAP net loss was $42.5 million, or $2.21 per share, versus GAAP net income of $86.1 million, or $4.75 per diluted share, in Q1 2024
Core adjusted net income was $26.6 million, or $1.33 per diluted share, compared with $1.20 per diluted share a year earlier
Ligand reaffirmed 2025 total revenue guidance of $180 million to $200 million and adjusted EPS guidance of $6.00 to $6.25
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ligand Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →